...buprenorphine; it received “tentative” approval by FDA in 2018.COVID course correction for Phase III of Biocon...
...this month. Equillium has U.S. and Canadian rights to the anti-CD6 mAb from Biocon Ltd. (NSE:BIOCON...
...HER1) – Epidermal growth factor receptorGPR84 – G protein-coupled receptor 84 BC Staff Alzumab, itolizumab (EQ001, anti-cd6, t1h) Equillium Biocon Moderna Bayer Galapagos Braeburn Genmab COVID-19 cov19count chs2020 cov19count...

...I-IIa trials for leukemia and lymphoma.Goldman injects cash into Biocon BiologicsBiocon Ltd. (NSE:BIOCON; BSE:532523) said its Biocon...

...the timetable, Kiran Mazumdar-Shaw, one of Immuneel’s co-founders, told BioCentury. Shaw is executive chairperson of Biocon...

...the board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder and executive chairperson of Biocon Ltd. (NSE:BIOCON...

...Staff Writer Mylan, Biocon launch long-acting insulin biosimilar in U.S.Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...in adults with Type II diabetes and adults and children with Type I diabetes (see “Biocon...

...Alzumab itolizumab among the drugs on its COVID-19 treatment protocol. With an Indian EUA for Alzumab, Biocon...
...it to succeed where IL-6 inhibitors have failed. Mazumdar-Shaw is executive chair of Biocon Ltd. (NSE:BIOCON...
...on Friday, Tata Capital Growth Fund invested Rs2.3 billion in Biocon Biologics Ltd., valuing the Biocon...

...$23.31 (731%) to $26.50 on Monday to reach a valuation of $468.6 million. Biocon Ltd. (NSE:BIOCON...
...alone, seven recovered and three died. According to Biocon, the survival benefit was statistically significant. Biocon...
...from the adaptive study (see “UK Approves Steroid” ). Sandi Wong, Assistant Editor Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon...

...from Biocon and Mylan has at last gained FDA’s approval to treat diabetes. Biocon Ltd. (NSE:BIOCON...
...claims for U.S. Patent 9,526,844 held by Sanofi (Euronext:SAN; NASDAQ:SNY) covering Lantus insulin glargine (see “Biocon...
...overcome two complete response letters; the second, issued in August 2019, had cited problems at Biocon’s...

...factor receptor superfamily member 10b TRAIL - Tumor necrosis factor-related apoptosis-inducing ligand Hongjiang Li, Staff Writer SCB-313 biosimilar etanercept (SCB-808) SCB-313 biosimilar etanercept...

...U.S. by Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN); Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...launched in January at a 22% discount. Steve Usdin, Washington Editor Teva Pharmaceutical Industries Ltd. Celltrion Inc. Genentech Inc. Roche Mylan N.V. Biocon...